Company intelligence / Profile preview

Ixchel Pharma

Davis, California, United States

Ownership: Private
Development stage: Other

Overview

Ixchel Pharma develops novel mitochondrial-targeted therapeutics, with its most advanced program focused on a small molecule, dimethyl fumarate (DMF), for the treatment of Friedreich’s ataxia, a rare neurodegenerative disorder[1][3]. The company previously had a collaboration with Forward Pharma for clinical development of this candidate, but the partnership was terminated due to a settlement between Forward Pharma and Biogen[3]. There is no public evidence of ongoing clinical trials or recent clinical data as of May 2025[4].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Forward Pharma (historical)Berkeley SkyDeck (investor/incubator)

Beyond the preview

Go deeper on Ixchel Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ixchel Pharma.

Explore the full profile